Peter Attia· MD
but at 25 milligrams per kilogram at least on some of the grants that I reviewed that was pretty good safety profile for epilepsy so you know not making any recommendations out there but I think 25 milligrams per kilogram seems to be within the realm of therapeutic efficacy and safety and this is being studied in humans and they're out of phase one so this is epileptic world yeah and I think there's some cancer trials going on too and I do think that synergize is really well once you create the environment where you put the press protocol into action then the cancer cells become even very selectively vulnerable to other things like the 2dg will inhibit a glycolytic pathway that drives the pentose phosphate pathway and that pentose phosphate pathway is responsible for enhancing the endogenous antioxidant capacity of cells so it makes the cancer cells even more vulnerable to oxidative stress the more you can inhibit the glycolytic pathways so to dg2 dichloro acetate is something that we've worked with to inhibit speedy h complex and that can be is DCA a drug that's been on the market for a long time it's a small molecule is yeah it's been on the market for a very long time what's it's normally used it's normal use is lactic acidosis actually so one of the side effects of metformin right is is once you start increasing the dose of metformin and